Upcoming
Elobixibat: The Breakthrough New Class of Drug in Chronic Constipation Management
Padma Shri Dr. Randhir Sud and Dr. Mayank...
25 Oct 2024 08:30:00 PM
Webinar Speakers
There are 2 speakers in this webinar
H2 tag- SEO Purpose
Elobixibat: The Breakthrough New Class of Drug in Chronic Constipation Management
Related Webinars
Close
Webinar Speakers
Topics Covered
Padma Shri Dr. Randhir Sud and Dr. Mayank Kabrawala the role of Elobixibat in the management of Chronic Constipation
Meet the Speakers
-
Fellowship in ERCP, D.M (Gastroenterology), M.D. (General Medicine), MBBS.Padma Shri Dr. Randhir Sud is the Chairman at Medanta Institute of Digestive & Hepatobiliary Sciences, Gurgaon. Dr. Randhir is credited with… Learn More
-
Dr. Mayank Kabrawala
MBBS, MD- Medicine, DMDr. Mayank Kabrawala is an experienced Gastroenterologist and Hepatologist from Surat with a clinical practice in digestive tract and liver… Learn More
Related Videos
-
GastroGastro Intestinal…GastroGastro Intestinal…
Clinical Safety and Tolerability of Vonoprazan by Prof. Hidekazu Suzuki
30 Jul 2024 -
Gastro Intestinal…GastroGastro Intestinal…Gastro
Clinical Efficacy of Vonoprazan in Gastric Acid Complications
30 Jul 2024 -
Gastro Intestinal…GastroGastro Intestinal…Gastro
Discerning the MOA of Vonoprazan in Gastric Acid Management by Prof. Hidekazu Suzuki
30 Jul 2024 -
GastroGastro Intestinal…GastroGastro Intestinal…
Gastric acid Suppression and The Unmet Needs of PPIs by Dr.Manu Tandan
30 Jul 2024 -
-
-
DiabetesCardiacDiabetesCardiac
Dapagliflozin and FDC's as an anti-Diabetic drug and beyond by Dr. Jahangir Rashid Beig
07 Jun 2024 -
DiabetesCardiacDiabetesCardiac
Diabetes Management in patient of Cardio- Vascular illness by Dr. Pravin Srivastava
07 Jun 2024 -
DiabetesCardiacDiabetesCardiac
Dapagliflozin - A Must in Armamentarium of Heart Failure by Dr. Srimannarayana J
07 Jun 2024 -
Videos Speakers
Related Videos
No result found. Choose another option for better results.
Videos Speakers
Profile Details
Join our sessions by completing the form below.